Voxelotor in sickle cell disease

Barbara J Bain^{1

2}, Jane Myburgh¹, Amanda Hann¹, D Mark Layton³

Affiliations

¹ Blood Sciences, Imperial College Healthcare NHS Trust, St Mary's Hospital, London, UK.
² Centre for Haematology, St Mary's Hospital Campus of Imperial College Faculty of Medicine, St Mary's Hospital, London, UK.
³ Department of Haematology, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK.

Free article

Barbara J Bain et al. Am J Hematol. 2022.

Free article

. 2022 Jun 1;97(6):830-832.

doi: 10.1002/ajh.26549. Epub 2022 Apr 8.

Barbara J Bain^{1

2}, Jane Myburgh¹, Amanda Hann¹, D Mark Layton³

¹ Blood Sciences, Imperial College Healthcare NHS Trust, St Mary's Hospital, London, UK.
² Centre for Haematology, St Mary's Hospital Campus of Imperial College Faculty of Medicine, St Mary's Hospital, London, UK.
³ Department of Haematology, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK.

No abstract available

References

1. Henry EER, Metaferia B, Li Q, et al. Treatment of sickle cell disease by increasing oxygen affinity of hemoglobin. Blood. 2021;138:1172-1181.
1. Rutherford NJ, Thoren KL, Shajani-Yia Z, Colbya JM. Voxelotor (GBT440) produces interference in measurements of hemoglobin S. Clin Chim Acta. 2018;482:57-59.